DBV Technologies | DBVT - Operating Profit

DBV Technologies reported $-18020000 in Operating Profit for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Operating Profit Change
Acadia Pharmaceuticals ACAD:US USD -46063000 15.2M
Alnylam Pharmaceuticals ALNY:US USD -188614000 146.01M
Amarin AMRN:US USD -5144000 57.69M
Biocryst Pharmaceuticals BCRX:US USD -46311000 28.87M
Biomarin Pharmaceutical BMRN:US USD -24500000 22.08M
Esperion Therapeutics ESPR:US USD -42513000 890K
Galectin Therapeutics GALT:US USD -8122000 1.54M
Halozyme Therapeutics HALO:US USD 74.51M 6.07M
Insmed INSM:US USD -151475000 23.78M
Intercept Pharmaceuticals ICPT:US USD -18024000 83.88M
IONIS PHARMACEUT IONS:US USD -208019000 148.86M
Neurocrine Biosciences NBIX:US USD 103.4M 15.6M
Ptc Therapeutics PTCT:US USD -200341000 132.15M
Sarepta Therapeutics SRPT:US USD -109408000 147.39M
Ultragenyx Pharmaceutical RARE:US USD -145628000 79.44M
United Therapeutics UTHR:US USD 175.6M 138.7M
YTE INCY:US USD 70.09M 68.28M